Q4FY26 results: 18 Indian companies to watch in 2026

A busy day for Q4FY26 earnings

A large set of listed companies is scheduled to announce January to March earnings for Q4FY26, putting several consumer, healthcare, real estate and media names in the spotlight. The list includes ITC, Aurobindo Pharma, Life Insurance Corporation of India, Max Healthcare Institute, Gail (India), Emami, Prestige Estates Projects, FSN E-Commerce Ventures (Nykaa), Page Industries, Honasa Consumer, Ashoka Buildcon, VA Tech Wabag, Sun TV Network, Quick Heal Technologies, Ramco Systems, RateGain Travel Technologies, Bikaji Foods International, Datamatics Global Services, Engineers India, and Icra. Market participants will track not just headline profit and revenue numbers, but also management commentary on demand, margins and any near-term risks. In this set, staples and consumer names are being watched closely for volume trends and marketing spends. IT and software-linked names on the list are also likely to be judged on deal commentary and growth visibility.

Companies scheduled to announce Q4FY26 results

The line-up spans both large caps and mid-caps, increasing the chance of sector-level read-throughs as results get released. In consumer, ITC, Emami, Page Industries, Nykaa and Honasa are key. In healthcare, Aurobindo Pharma and Max Healthcare are among the prominent names. Gail (India), Engineers India and VA Tech Wabag bring an industrial and energy angle, while Prestige Estates adds a real estate lens. Sun TV Network represents the media segment, and Quick Heal and Ramco Systems feature from the tech side. RateGain and Datamatics add further coverage of IT services and travel tech.

ITC: low single-digit growth expected by brokerages

Brokerage estimates cited in the report suggest ITC is expected to post low single-digit growth in Q4FY26. Within the business mix, cigarette volumes are described as likely to remain subdued. Analysts also believe ongoing geopolitical tensions are unlikely to have a material impact on staple companies such as ITC in the March quarter, due to limited exposure to West Asia. For investors, the key items typically tracked in ITC’s results include volume commentary, margin movement, and the contribution of non-cigarette FMCG and other segments. The report does not provide a specific consensus number for ITC’s Q4FY26 revenue or profit, but it flags the direction of growth expectations and the volume outlook.

Nykaa (FSN E-Commerce Ventures): Q4 preview points to higher YoY profit

For FSN E-Commerce Ventures, the parent of Nykaa, the preview in the report indicates a strong year-on-year rise in profitability. Net profit is expected to increase 226.44% year-on-year to an average of ₹65.06 crore, compared with ₹19.93 crore a year ago. But sequentially, profit after tax (PAT) is expected to decline 17% from ₹78.8 crore in Q3FY26. Revenue for the quarter is estimated to rise about 27% year-on-year to ₹2,613 crore from ₹2,061.8 crore. On a quarter-on-quarter basis, revenue is expected to fall 9% from ₹2,873.3 crore.

Honasa Consumer: results date, consensus and what the company expects

The report states Honasa Consumer (Mamaearth parent) is set to announce its Q4 FY26 results on May 10, 2026. The board is expected to approve Q4 and full-year FY26 results, consider a final dividend for FY26, and provide management’s first formal FY27 business outlook. Analyst consensus Q4 FY26 revenue estimate for Honasa Consumer is ₹580 crore, with a PAT estimate of ₹14 crore. Q3 FY26 actual revenue is stated at ₹527 crore.

Separately, the report notes a “beat versus analyst consensus” would be revenue above ₹580 crore with EBITDA at 5%. It also adds that actual results may differ based on operating conditions. On business commentary, the company expects to deliver growth in the late twenties in Q4 FY26, driven by momentum across focus segments. After adjusting for the Flipkart group’s change in revenue recognition policy, reported growth is projected to be in the early twenties. Mamaearth is expected to grow in the teens, while younger brands are expected to sustain momentum with mid-twenties growth.

Honasa stock levels and dividend expectation mentioned

The report includes multiple Honasa share price references from different points in time. It says Honasa Consumer trades at ₹285 as of April 2026, with a 52-week high of ₹520 and a 52-week low of ₹248, and a 1-year return of -45%. It also provides a separate price update: as of 12/02/2026 at 15:30 PM, Honasa Consumer’s share price stands at ₹299.25, up ₹7.29, with an intraday range of ₹289.65 to ₹303.2, and a 1-year return of 40.8%.

On dividends, the report states Honasa Consumer is expected to declare ₹0 as final dividend for FY26, subject to board approval on May 10, 2026 and subsequent AGM shareholder approval.

A look back: Honasa Q4FY25 and FY25 financial highlights in the report

The report also provides Q4FY25 and FY25 numbers for Honasa Consumer, highlighting revenue growth but softer profitability versus the previous year. In Q4FY25, revenue is given at ₹534 crore, up 13% year-on-year from ₹471 crore, with underlying volume growth of 21.2%. EBITDA is shown at ₹27 crore versus ₹33 crore in Q4FY24, and EBITDA margin at 5.1% versus 7%. Net profit is listed at ₹25 crore in Q4FY25 versus ₹30.5 crore in Q4FY24.

For the full year FY25, the report states revenue of ₹2,066.9 crore, up 8% from ₹1,919.9 crore in FY24, while net profit fell 32% to ₹72.6 crore from ₹110.5 crore. Gross margin in Q4FY25 improved to 70.7%, up 76 basis points year-on-year, with gains linked to better product mix and operational efficiencies. The report adds that EBITDA was impacted due to a 20% uptick in other expenses.

Market moves and Q4FY25 result snapshots: ITC, Sun Pharma, Honasa

The report also summarises market reaction around Q4FY25 results for ITC, Sun Pharma and Honasa. It says shares of ITC and Honasa advanced, while Sun Pharma and HFCL shares declined. For Sun Pharma Q4 FY25 (consolidated, YoY), it states the share price fell 4.78% to ₹1,636.60, revenue rose 8% to ₹12,959 crore (versus ₹11,983 crore), EBITDA rose 22.4% to ₹3,716 crore (versus ₹3,035 crore), and net profit fell 19% to ₹2,154 crore (versus ₹2,659 crore). It also notes an exceptional loss of ₹362 crore versus ₹102 crore year-on-year, and India formulation sales at ₹4,213 crore (₹42,130 million), up 13.6%.

For ITC Q4FY25 (standalone, YoY), the report states the share price rose 1.85% to ₹434, revenue rose 9.4% to ₹17,248.15 crore, EBITDA rose 2.5% to ₹5,986 crore, margin was 34.7% versus 37.1%, and net profit from continued operations rose 0.8% to ₹4,874 crore.

For Honasa Q4 FY25 (consolidated, YoY), it states the share price rose 14.12% to ₹314, revenue rose 13.3% to ₹533.5 crore, EBITDA fell 17.6% to ₹27.1 crore, margin was 5.1% versus 7%, and net profit fell 17.8% to ₹25 crore.

Key numbers table: estimates, dates and reference points

Result highlights table: Q4FY25 snapshots mentioned

Why these updates matter for investors

The Q4FY26 earnings slate brings together companies that can influence sentiment across staples, beauty and personal care, pharma, and industrials. For ITC, the focus highlighted in the report is volume behaviour in cigarettes and whether subdued trends persist. For Nykaa, the report’s estimate implies a sharp year-on-year profit jump, but also flags a quarter-on-quarter dip in both PAT and revenue compared with Q3FY26. For Honasa, the most tracked points are the consensus revenue and PAT, the expectation of a zero final dividend for FY26, and management’s first formal FY27 outlook.

Conclusion

Q4FY26 results from ITC, Nykaa, Honasa and a broad set of other companies are expected to provide fresh data points on demand, margins and near-term execution. For Honasa, the report specifically flags May 10, 2026 as the scheduled results date, along with a board discussion on FY26 numbers, a final dividend and an FY27 business outlook.